The Myeloproliferative Neoplasms Channel is supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
VJVirtual | Impact of COVID-19 on treatment of MPNs
Naveen Pemmaraju, MD, of the MD Anderson Cancer Center, Houston, TX, discusses the impact of the current COVID-19 pandemic on the treatment of patients with myeloproliferative neoplasms (MPNs), highlighting the reduced access to routine healthcare in the outpatient setting. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).
